CGEN · Compugen Ltd. Ordinary Shares
View on chartInsiders & Stakes
| David Silberman Chief Financial Officer | ▲ Buy | Grant | 55,000 Shares held | 7/29/2026 | View profile |
| Zurit Levine SVP, Business Development | ▲ Buy | Grant | 47,375 Shares held | 7/29/2026 | View profile |
| Russo Sharon Kredo SVP, Research & Discovery | ▲ Buy | Grant | 37,500 Shares held | 7/29/2026 | View profile |
| Michelle Mahler Chief Medical Officer | ▲ Buy | Grant | 36,625 Shares held | 7/29/2026 | View profile |
| Savitzky Kinneret Livnat Director | ▲ Buy | Grant | 20,850 Shares held | 7/29/2026 | View profile |
| Sanford S. Zweifach Director | ▲ Buy | Grant | 20,180 Shares held | 7/29/2026 | View profile |
| Gilead Halevy Director | ▲ Buy | Grant | 18,907 Shares held | 7/29/2026 | View profile |
| Eran Perry Director | ▲ Buy | Grant | 17,500 Shares held | 7/29/2026 | View profile |
| Mathias Hukkelhoven Director | ▲ Buy | Grant | 17,500 Shares held | 7/29/2026 | View profile |
| Eran Ophir President and CEO | ▼ Sell | Open Market | 11,375 Shares held | 4/24/2026 | View profile |
Transaction History
| Zurit Levine | ▲ Buy | Grant | 18,000 | $0 | 7/29/2026 |
| David Silberman | ▲ Buy | Grant | 19,500 | $0 | 7/29/2026 |
| Eran Perry | ▲ Buy | Grant | 7,500 | $0 | 7/29/2026 |
| Russo Sharon Kredo | ▲ Buy | Grant | 18,000 | $0 | 7/29/2026 |
| Savitzky Kinneret Livnat | ▲ Buy | Grant | 7,500 | $0 | 7/29/2026 |
| Mathias Hukkelhoven | ▲ Buy | Grant | 7,500 | $0 | 7/29/2026 |
| Gilead Halevy | ▲ Buy | Grant | 7,500 | $0 | 7/29/2026 |
| Sanford S. Zweifach | ▲ Buy | Grant | 7,500 | $0 | 7/29/2026 |
| Michelle Mahler | ▲ Buy | Grant | 13,500 | $0 | 7/29/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 1,875 | $2K | 7/9/2026 |
| Zurit Levine | ▼ Sell | Open Market | 1,875 | $5K | 7/9/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 2,000 | $2K | 4/24/2026 |
| Zurit Levine | ▼ Sell | Open Market | 2,000 | $6K | 4/24/2026 |
| Eran Ophir | ▲ Buy | Option Exercise | 5,000 | $4K | 4/24/2026 |
| Eran Ophir | ▼ Sell | Open Market | 5,000 | $16K | 4/24/2026 |
| Eran Ophir | ▲ Buy | Option Exercise | 5,000 | $4K | 4/14/2026 |
| Eran Ophir | ▼ Sell | Open Market | 5,000 | $15K | 4/14/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 2,000 | $2K | 4/14/2026 |
| Zurit Levine | ▼ Sell | Open Market | 2,000 | $6K | 4/14/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 1,125 | $933 | 4/10/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 2,000 | $2K | 4/10/2026 |
| Zurit Levine | ▼ Sell | Open Market | 3,125 | $8K | 4/10/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 4,375 | $4K | 4/8/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 1,000 | $1K | 4/8/2026 |
| Zurit Levine | ▼ Sell | Open Market | 5,375 | $13K | 4/8/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 2,500 | $2K | 4/7/2026 |
| Zurit Levine | ▼ Sell | Open Market | 2,500 | $6K | 4/7/2026 |
| Zurit Levine | ▼ Sell | Open Market | 3,500 | $8K | 4/1/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 2,500 | $2K | 4/1/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 1,000 | $1K | 4/1/2026 |
| Eran Ophir | ▲ Buy | Option Exercise | 5,625 | $5K | 4/1/2026 |
| Eran Ophir | ▼ Sell | Open Market | 5,625 | $12K | 4/1/2026 |
| Zurit Levine | ▲ Buy | Option Exercise | 11,875 | $10K | 3/26/2026 |
| Zurit Levine | ▼ Sell | Open Market | 11,875 | $24K | 3/26/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Compugen to Host Virtual KOL Event on COM701
Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.
Compugen to Host Virtual KOL Event on COM701. Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.